All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Orelabrutinib
Therapeutic Area: Immunology Product Name: ICP-022
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: WuXi STA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2021
Details:
The National Drug Administration of China (NMPA) Drug Evaluation Center (CDE) has prioritized the new drug application (NDA) for Orelabrutinib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Telitacicept
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2020
Details:
US FDA granted Fast Track designation for RC18, for the treatment of systemic lupus erythematosus (SLE). RC18 shows statistically significant improvement for patients at multiple doses.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
